A row over who was responsible for developing the Spikevax COVID-19 vaccine has spilled out into the public domain.
The New York Times reported on a year-long dispute between US biotech Moderna (Nasdaq: MRNA) and the National Institutes of Health (NIH), citing a letter written by the campaign group Public Citizen to NIH director Francis Collins.
Public Citizen wrote to express its concern that patent applications filed by Moderna did not list federal scientists as co-inventors of the jab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze